James F. Howard, MD

Nicholas Silvestri, MD, FAAN, and Tuan Vu, MD, provide an overview of the current FDA-approved targeted therapies for the treatment of MG.

Experts in neurology highlight taking age and quality of life into consideration when approaching treatment of MG, as well as comment on the standard of care for patients.

Expert neurologists discuss the factors that guide treatment selection in MG, shifting the framework to take patient preferences into account.

Ali Habib, MD, comments on the prevalence of MG in older patients and the increasing rate of hospitalization and mortality within this group.

Beth Stein, MD, reviews critical steps towards diagnosing MG, taking a look at the different types of reliable testing for the disease.

Experts in neurology comment on fatigue and fluctuation of symptoms in MG and how that can contribute to a delay in diagnosis.

Expert neurologists discuss the presentation of myasthenia gravis (MG), focusing on the variability of symptoms from patient to patient.

The Distinguished Professor of Neuromuscular Disease at University of North Carolina School of Medicine offered his insight into the newly approved Argenx agent, marketed as Vyvgart. [WATCH TIME: 3 minutes]

The Distinguished Professor of Neuromuscular Disease at UNC School of Medicine spoke to the results of the phase 3 ADAPT trial, and what else he’s like to see investigated with efgartigimod.

The Distinguished Professor of Neuromuscular Disease at UNC School of Medicine discussed the findings of the ADAPT trial and the promise efgartigimod has shown to be an effective agent for generalized myasthenia gravis.